[Combination chemotherapy with methotrexate (MTX), vincristine (VCR), cisplatinum (CDDP), cyclophosphamide (CPM), adriamycin (ADM), and bleomycin (BLM); MVP-CAB in patients with advanced urothelial tract cancer].
Fujii
A
A
Morishita
S
S
Nakamura
I
I
Oka
Y
Y
Ohshima
H
H
Nagata
H
H
Iwamoto
T
T
Izumi
T
T
Miyasaki
Z
Z
Ito
N
N
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D012074:Remission Induction; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000401:mortality; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D008727:Methotrexate